作者
Olga C Aroniadis, Lawrence J Brandt, Caterina Oneto, Paul Feuerstadt, Alex Sherman, Allan W Wolkoff, Zain Kassam, Rotem Gura Sadovsky, Ryan J Elliott, Shrish Budree, Mimi Kim, Marla J Keller
发表日期
2019/9/1
期刊
The Lancet Gastroenterology & Hepatology
卷号
4
期号
9
页码范围
675-685
出版商
Elsevier
简介
Background
Faecal microbiota transplantation (FMT) has shown promise in alleviating the symptoms of irritable bowel syndrome (IBS); however, controlled data on this technique are scarce. The aim of this clinical trial was to assess the efficacy of FMT in alleviating diarrhoea-predominant IBS (IBS-D).
Methods
We did a double-blind, randomised, placebo-controlled crossover trial in patients aged 18–65 years with moderate-to-severe IBS-D defined by an IBS-Symptom Severity Score (IBS-SSS) of more than 175, recruited from three US centres. Patients were randomly assigned (1:1) in blocks of four with a computer-generated randomisation sequence to receive FMT capsules followed by identical-appearing placebo capsules, or placebo capsules followed by FMT capsules. All participants and study team members were masked to randomisation. An independent staff member assigned the treatments according to …
学术搜索中的文章
OC Aroniadis, LJ Brandt, C Oneto, P Feuerstadt… - The Lancet Gastroenterology & Hepatology, 2019